Skip to main content

Health condition

Hepatoblastoma, the childhood liver tumour that responds well to a clear treatment plan.

Rare, but the most common liver cancer in young children - and one where chemotherapy, surgery and, where needed, transplant now achieve strong outcomes.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against SIOPEL, COG and NHS specialised commissioning standards you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK paediatric liver tumour pathways, including PRETEXT staging and AFP-guided monitoring.

Key facts

Hepatoblastoma at a glance.

The essentials, in plain English - what it is, who it affects, and how it's treated in the UK today.

  • What it is

    The most common paediatric liver malignancy - a tumour of immature liver cells, typically diagnosed under the age of three.

  • Associations

    Beckwith-Wiedemann syndrome, familial adenomatous polyposis (FAP), low birth weight and prematurity, and Wnt/beta-catenin pathway mutations.

  • Key marker

    Alpha-fetoprotein (AFP) is elevated in over 90% of cases - used for diagnosis, treatment response and long-term surveillance.

  • Presentation

    Abdominal mass or distension, weight loss, and occasionally precocious puberty or jaundice in advanced disease.

  • Staging system

    PRETEXT staging on cross-sectional imaging guides whether upfront surgery, chemotherapy first, or transplant is the right path.

  • Where it is treated

    Specialist commissioned paediatric liver tumour centres - including Birmingham Children’s Hospital, Great Ormond Street and Leeds - within the SIOPEL network.

Why this guide matters

A rare diagnosis, but a well-mapped pathway.

Hearing "liver tumour" about your child is frightening. These three points shape everything else on this page.

  • AFP is a powerful marker

    Alpha-fetoprotein is elevated in over 90% of cases and tracks response to treatment and recurrence throughout care.

  • Chemotherapy usually comes first

    Cisplatin-based neoadjuvant chemotherapy shrinks the tumour before surgery is even considered, in almost every child.

  • Specialist centres, one network

    All care runs through specialist commissioned paediatric liver tumour centres within the SIOPEL network - not a general hospital.

How the diagnosis is made

From a mass on examination to a clear staging plan.

The steps a UK specialist paediatric liver tumour team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Recognising the presentation

    A painless abdominal mass or distension in a child under three, sometimes with weight loss - the trigger for urgent assessment.

  2. 02

    Assessing

    AFP and liver function bloods

    Alpha-fetoprotein is markedly elevated in the great majority of cases and, alongside LFTs, is the first strong clue.

  3. 03

    Confirming

    Ultrasound of the abdomen

    Usually the first imaging test - confirms a liver mass and helps plan more detailed cross-sectional imaging.

  4. 04

    Confirming

    CT or MRI abdomen for PRETEXT staging

    Specialist commissioned cross-sectional imaging maps the tumour against the liver’s segments to assign a PRETEXT stage.

  5. 05

    Confirming

    Biopsy and histopathology

    Specialist commissioned paediatric pathology confirms the diagnosis and distinguishes epithelial from mixed epithelial-mesenchymal subtypes.

  6. 06

    Preparing

    Chest CT for metastases

    The lungs are the most common site of spread, so staging always includes specialist commissioned chest imaging.

  7. 07

    Preparing

    Specialist MDT review

    A specialist commissioned paediatric liver tumour MDT - oncology, hepatobiliary surgery and pathology - agrees the treatment pathway.

Typical timeline: a first scan to a full staging picture within one to two weeks.

Symptoms

What hepatoblastoma actually looks like.

Often subtle at first - an abdominal mass noticed by a parent or found on examination. And the features that mean it's time to seek urgent review.

  • Abdominal mass or distension

    Often the first and only sign - a painless swelling or firmness noticed by a parent or on routine examination.

  • Weight loss and poor appetite

    Systemic features that can accompany a growing liver tumour, sometimes mistaken for a feeding problem.

  • Precocious puberty

    Some tumours secrete beta-hCG, which can trigger early signs of puberty - an unusual but recognised presentation.

  • Jaundice in advanced disease

    Yellowing of the skin and eyes usually reflects more extensive or advanced disease and warrants urgent review.

  • Abdominal pain or discomfort

    Can occur as the tumour enlarges or presses on surrounding structures.

  • Anaemia or fatigue

    Non-specific but sometimes present alongside the mass, reflecting the tumour’s systemic effects.

  • Incidental finding

    Occasionally picked up on imaging done for another reason, particularly in children with known risk syndromes.

  • Red flag - rapid abdominal swelling

    Fast-growing abdominal swelling in an infant or toddler needs urgent same-day medical assessment.

Treatment

How hepatoblastoma is treated in the UK.

Chemotherapy first to shrink the tumour, surgery to remove it, and transplant or further chemotherapy where needed - all specialist commissioned.

  • Neoadjuvant chemotherapy (PLADO)

    Cisplatin-based chemotherapy given before surgery to shrink the tumour and make complete resection possible - specialist commissioned.

  • Surgical resection

    Partial hepatectomy is the definitive treatment once the tumour has responded to chemotherapy - specialist commissioned paediatric hepatobiliary surgery.

  • Liver transplant

    For unresectable disease or PRETEXT IV tumours, transplantation offers a curative option - specialist commissioned, see our liver transplant guide.

  • Adjuvant chemotherapy

    Further chemotherapy after surgery reduces the risk of recurrence - specialist commissioned and tailored to risk group.

  • AFP surveillance

    Regular alpha-fetoprotein monitoring after treatment is the main way recurrence is picked up early - specialist commissioned follow-up.

  • High-risk and relapsed disease

    Irinotecan and doxorubicin-based regimens are used for higher-risk or relapsed tumours - specialist commissioned oncology.

  • Long-term survivorship follow-up

    Growth, development, hearing and kidney function are monitored for late effects of chemotherapy - specialist commissioned survivorship care.

  • Specialist MDT coordination

    Paediatric oncology, hepatobiliary surgery, and organisations such as the Children’s Liver Disease Foundation work together throughout care.

What this guide is based on

The sources behind every claim on this page.

International paediatric oncology protocols and UK specialised commissioning standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your child's specialist paediatric liver tumour team knows their history and can tell you which parts apply. If in doubt, get seen.

  • SIOPEL (International Childhood Liver Tumours Strategy Group). Treatment protocols for hepatoblastoma.

  • Children’s Oncology Group (COG). Hepatoblastoma risk stratification and treatment guidelines.

  • NHS England. Specialised commissioning standards for paediatric liver tumour services.

  • Children’s Liver Disease Foundation. Patient and family information on hepatoblastoma.

Red flags

When hepatoblastoma needs urgent attention.

Most children move through this pathway calmly on a planned basis. These are the situations that need same-day medical review.

  • Rapidly enlarging abdominal mass

    A fast-growing swelling in an infant or young child needs same-day medical assessment, not a routine appointment.

  • Jaundice

    Yellowing of the skin or eyes in a child with a known or suspected liver mass suggests advanced disease and needs urgent review.

  • Signs of tumour rupture or bleeding

    Sudden severe abdominal pain, pallor or collapse can indicate rupture - this is a medical emergency.

  • Precocious puberty in a young child

    Early pubertal signs in a toddler should prompt investigation for a beta-hCG secreting tumour, including hepatoblastoma.

  • Breathlessness or persistent cough

    Could reflect pulmonary metastases and needs prompt specialist assessment.

  • Family history of FAP

    Children in families with familial adenomatous polyposis carry a higher risk and may need closer surveillance.

  • Beckwith-Wiedemann syndrome

    Known association with hepatoblastoma - affected children are often enrolled in structured screening programmes.

  • Failure to thrive with abdominal swelling

    Poor weight gain alongside a palpable abdominal mass should be assessed urgently rather than watched.

  • Post-treatment AFP rise

    A rising alpha-fetoprotein after apparently successful treatment is the earliest sign of relapse and needs immediate specialist review.

Living with it

A treatable diagnosis, with a clear path through it.

Four things that make the biggest difference for families - keeping AFP checks on schedule, leaning on specialist support, watching development, and asking about family risk.

A quiet reminder

Regular follow-up is what keeps outcomes strong.

Steady, scheduled AFP checks and specialist review over years - not just the treatment itself - are what protect the long-term outlook.

  1. 01 Monitor

    Keep AFP checks on schedule

    Regular alpha-fetoprotein blood tests are the most sensitive way to catch recurrence early - don’t miss follow-up appointments.

  2. 02 Support

    Lean on specialist teams

    Paediatric liver tumour centres and organisations like the Children’s Liver Disease Foundation offer practical and emotional support for families.

  3. 03 Watch

    Track growth and development

    Long-term follow-up watches for late effects of chemotherapy, including hearing, kidney function and growth.

  4. 04 Plan

    Ask about genetic and family risk

    If there’s a family history of FAP or Beckwith-Wiedemann syndrome, ask your team about genetic counselling and screening for siblings.

Frequently asked

Everything we get asked about hepatoblastoma.

Quick answers on causes, AFP testing, staging, chemotherapy, surgery and outlook.

  • What is hepatoblastoma?

    Hepatoblastoma is the most common malignant liver tumour in children, typically diagnosed before the age of three. It arises from immature liver cells and is usually detected through an abdominal mass, weight loss or an elevated alpha-fetoprotein (AFP) blood test.

  • What causes hepatoblastoma?

    In most cases there is no identifiable cause, but recognised associations include Beckwith-Wiedemann syndrome, familial adenomatous polyposis (FAP), low birth weight or prematurity, and mutations in the Wnt/beta-catenin signalling pathway.

  • How is hepatoblastoma diagnosed?

    Diagnosis combines a markedly elevated AFP blood test, ultrasound followed by specialist commissioned CT or MRI imaging for PRETEXT staging, a chest CT to check for lung spread, and biopsy with specialist commissioned histopathology to confirm the tumour subtype.

  • What does PRETEXT staging mean?

    PRETEXT (PRETreatment EXTent of disease) is a staging system based on cross-sectional imaging that maps how much of the liver is involved before any treatment starts. It guides whether upfront surgery, chemotherapy first, or liver transplant is the most appropriate pathway.

  • How is hepatoblastoma treated?

    Most children receive cisplatin-based neoadjuvant chemotherapy to shrink the tumour, followed by surgical resection - specialist commissioned partial hepatectomy. Tumours that cannot be safely removed, including PRETEXT IV disease, may need a liver transplant. Adjuvant chemotherapy and long-term AFP surveillance follow.

  • What is the outlook for children with hepatoblastoma?

    Outlook has improved substantially with modern chemotherapy and surgical protocols, and many children achieve long-term cure, particularly with earlier-stage disease. Ongoing AFP monitoring and specialist commissioned survivorship follow-up track both recurrence risk and the long-term effects of treatment.

Related content

Keep reading.